Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00465426 |
HIV-infected patients treated with combination antiretroviral therapy demonstrate metabolic abnormalities that may predispose them to cardiovascular disease. In HIV-infected patients we will investigate progression rates of cardiovascular disease and assess whether these progression rates are predicted by increased inflammatory indices.
Condition |
---|
HIV Infections Cardiovascular Disease |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Assessment of Cardiovascular Risk in HIV Patients |
blood will be frozen for end of study analysis for insulin, CRP, adiponectin, TNF-α, sTNFR2, IL-6, PAI-1, MCP-1
Estimated Enrollment: | 150 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | April 2011 |
Groups/Cohorts |
---|
1
HIV Positive men and women 18-65 years of age
|
2
HIV negative men and women 18-65 years of age
|
HIV-infected patients treated with combination antiretroviral (ARV) therapy increasingly demonstrate metabolic abnormalities, including dyslipidemia, insulin resistance and body composition abnormalities that may predispose them to cardiovascular disease (CVD). Initial studies suggest increased carotid intima-media thickness (IMT) and endothelial dysfunction in this population. Increased carotid IMT over time has been demonstrated in HIV-infected patients compared to control subjects. However, traditional risk factors, such as dyslipidemia, diabetes mellitus and body composition changes alone do not fully predict increased cardiovascular disease in HIV-infected patients. One possible explanation is increased inflammation, related directly to effects of ARV therapy or indirectly from changes in fat distribution. In preliminary studies, our group has shown that changes in fat distribution were highly predictive of TNF and IL-6, as well as adiponectin, and that specific inflammatory cytokines were related in cross-sectional studies to increased IMT. In the proposed study we will investigate using detailed methodologies the relationship between adipocytokine concentrations and subclinical atherosclerosis in both cross-sectional and longitudinal studies. We will determine in HIV-infected patients on ARVs for greater than 6 months, progression rates of IMT and endothelial function and whether progression rates are predicted by increased inflammatory indices, controlling for traditional risk factors, and body composition changes. We will test the hypothesis that inflammation, more than traditional risk factors and ARV use, mediates subclinical atherosclerotic disease in HIV-infected patients.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Flyers and advertisements regarding this study will be posted in community centers and newspapers
Inclusion Criteria:
Inclusion Criteria for Group 1 (HIV-infected group)
Inclusion Criteria for Group 2 (HIV Negative, Healthy Control, age and BMI matched to HIV subjects)
Exclusion Criteria:
Exclusion Criteria for Group 1 (HIV-infected group)
Criteria for Group 2 (HIV Negative, Healthy Control, age and BMI matched to HIV subjects)
Contact: Kathleen V Fitch, MSN, NP | 617-724-8015 | kfitch@partners.org |
Contact: Sara Dolan, MSN, NP | 617-726-1423 | slooby@partners.org |
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Principal Investigator: Steven K Grinspoon, MD | |
Sub-Investigator: Kathleen V Fitch, MSN, NP | |
Sub-Investigator: Sara Dolan, MSN, NP |
Principal Investigator: | Steven K Grinspoon, MD | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( Steven K. Grinspoon, MD ) |
Study ID Numbers: | DK49302-10AR |
Study First Received: | April 24, 2007 |
Last Updated: | January 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00465426 |
Health Authority: | United States: Federal Government |
HIV Infection Cardiovascular Disease Antiretroviral Therapy Inflammatory Markers Treatment Experienced |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases |
Lentivirus Infections Cardiovascular Diseases Infection |